• Users Online: 110
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2016  |  Volume : 41  |  Issue : 3  |  Page : 111-115

Lower Fas-associated phosphatase-1 expression predicted poor outcome in acute myeloid leukemia patients


1 Haematology Unit, Department of Clinical Pathology, Faculty of Medicine, Menoufia University, Menoufia, Egypt
2 Department of Clinical Pathology, Shebin El Kom Teaching Hospital, Shebin El Kom, Egypt
3 Department of Haemato-Oncology, National Cancer Institute, Cairo, Egypt
4 Department of Biochemistry, National Liver Institute, Menoufia University, Menoufia, Egypt
5 Department of Clinical Pathology, Menoufia University, Menoufia, Egypt

Correspondence Address:
Nahla F.A. Osman
Haematology Unit, Department of Clinical Pathology, Faculty of Medicine, Menoufia University, Shebin El Kom
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1110-1067.196175

Rights and Permissions

Background Fas-associated phosphatase-1 (FAP-1) mediates tumor suppressor and tumor promoter effects through the inhibition of oncogenic tyrosine kinases and apoptosis, respectively. It was claimed responsible for the pathogenesis of some cancers; nevertheless, its role in acute myeloid leukemia (AML) is not clear. Patients and Methods FAP-1 expression was measured in 20 new AML patients and 12 apparently healthy individuals using real-time PCR. Results FAP-1 expression was significantly lower in AML patients compared with controls (P<0.001). Patients with relatively higher FAP-1 expression had significantly higher hemoglobin and platelets but lower white cell count (WCC) and lactic dehydrogenase (LDH) (P<0.001), thus reflecting lower tumor burden in this group. Patients’ response was assessed on day 28 after chemotherapy; we found that one of seven patients with FAP-1 expression up to 0.03945 achieved complete remission (CR) compared with eight of 13 patients with levels more than 0.03945. FAP-1 levels predicted the response in the subgroup with normal karyotype and in those with no FLT3-ITD as the majority of those with higher levels achieved CR (77.8 and 80%, respectively), whereas CR was seldom achieved in those with low levels. Conclusion Our data showed significantly reduced FAP-1 expression in AML patients. FAP-1 can be a useful tool in identifying patient’s risk in AML as the level of expression predicted the response.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1023    
    Printed24    
    Emailed0    
    PDF Downloaded100    
    Comments [Add]    

Recommend this journal